Learn about who we are, what we believe
and the people who lead us
Discover our unique scientific approach
for diseases with high unmet need
The first and only FDA-approved
treatment for Demodex blepharitis
Explore the possibilities of our robust pipeline
to address significant unmet patient needs
Find additional corporate
and stock information
Important Safety Information:
Most common side effects: Most common side effect in clinical trials was stinging and burning in 10% patients. Other side effects in less than 2% of patients were chalazion/hordeolum and punctate keratitis.
Please see full Important Safety Information at XDEMVY.com.
Important Safety Information:
Most common side effects: Most common side effect in clinical trials was stinging and burning in 10% patients. Other side effects in less than 2% of patients were chalazion/hordeolum and punctate keratitis.
Please see full Important Safety Information at XDEMVY.com.
Click, hold and slide to see the results experienced by a real patient with DB.
Results after full 6 weeks of treatment
Results may vary.
Meet Emily
Meet Fernanda
Meet Griff
1. XDEMVY [prescribing information]. Tarsus Pharmaceuticals, Inc; 2023. 2. Fromstein SR, Harthan JS, Patel J, Opitz DL. Demodex blepharitis: clinical perspectives. Clin Optom (Auckl). 2018;10:57-63.
Our Terms of Use and Privacy Policy have changed.
By clicking accept, you agree that you have read and will abide by these new terms.
